Personalised Cancer Medicine Flashcards 2025
Indications determined by the organ of origin
Gastric Cancer
Standard
Recommended
Currently not recommended
- HER2
- Microsatellite Instability*
- PDL-1
- VEGFR
- EGFR
- MET
- EBV
* By either IHQ (MLH1, PMS2, MSH2 and MSH6) or by Genomic studies (BAT25 and BAT26, D2S123, D5S346 and D17S250).
The Standard category is based on current treatment indications with approved funding by the Spanish National Health System.
The Recommended category is based on currentrecommendations by EMEA and FDA.
The Recommended category is based on currentrecommendations by EMEA and FDA.
References:
1. Alsina Maqueda M, Teijo Quintáns A, Cuatrecasas M, Fernández Aceñero MJ, Fernández Montes A, Gómez Martín C, Jiménez Fonseca P, Martínez Ciarpaglini C, Rivera Herrero F, Iglesias Coma M. Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). Clin Transl Oncol. 2025 Mar 12. doi: 10.1007/s12094-025-03865-6.
2. Shitara K, Fleitas T, Kawakami H, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer. ESMO Open. 2024;9(2):102226. doi:10.1016/j.esmoop.2023.102226.
